**Abstract**

***Objective:*** *Hyperprolactinemia is an important but often overlooked side effect of antipsychotics. Addition of and switching to aripiprazole normalized antipsychotics-induced hyperprolactinemia in several studies. However, there was no study that directly compared the effectiveness and safety of both strategies.*

**Method:** A total 52 patients with antipsychotics-induced hyperprolactinemia were recruited. Aripiprazole was added to patients with mild hyperprolactinemia (serum prolactin level lower than 50ng/ml). Patients with severe hyperprolactinemia (serum prolactin level higher than 50ng/ml) were randomized to aripiprazole addition group (adding aripiprazole to previous antipsychotics) or switching group (switching previous antipsychotics to aripiprazole). Serum prolactin levels, menstrual disturbances, sexual dysfunctions, psychopathologies, quality of life were measured at weeks 0, 1, 2, 4, 6 and 8.

**Results:** Both addition and switching strategies significantly reduced serum prolactin levels (*F*(1, 199)=76.09, *p*\<0.001) and menstrual disturbances (χ^2^=63.86, *df*=5, *p*\<0.001) over time and they improved sexual dysfunctions (χ^2^=12.03, *df*=5, *p*=0.03) in all groups. In patients with severe hyperprolactinemia, number of patients with hyperprolactinemia (χ^2^=6.30, *df*=1, *p*=0.01) and menstrual disturbance (χ^2^=4.31, *df*=1, *p*=0.04) in switching group was significantly lower than that in addition group at week 8.

**Conclusion**: Both addition and switching strategies were effective in resolving antipsychotics-induced hyperprolactinemia and hyperprolactinemia related adverse events including menstrual disturbances and sexual dysfunctions. These findings suggest that switching to aripiprazole may be more effective in normalizing hyperprolactinemia and improving hyperprolactinemia related adverse events in patients with schizophrenia.
